RPH-002

DRUG2 trials

Sponsors

R-Pharm

Conditions

Head and Neck Squamous Cell Carcinoma

Phase 1

A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

CompletedNCT07435311

R-PharmHead and Neck Squamous Cell Carcinoma

Start: 2020-06-15End: 2024-07-17Updated: 2026-02-27

Phase 3

A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Active, not recruitingNCT07435324

R-PharmHead and Neck Squamous Cell Carcinoma

Start: 2024-08-08End: 2026-06-21Updated: 2026-02-27